A phase II trial of subcutaneous Amifostine and radiation therapy in patients with head and neck cancer

被引：39
|
作者：
Anné, PR
Curran, WJ
机构：
[1] Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA USA
[2] Med Oncol Allegheny Gen Hosp, Pittsburgh, PA USA
来源：
SEMINARS IN RADIATION ONCOLOGY | 2002年 / 12卷 / 01期
关键词：
D O I：
10.1053/srao.2002.31358
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [21] Randomized phase III trial of postoperative radiochemotherapy ± amifostine in head and neck cancer -: Is there evidence for radioprotection?
    Vacha, P
    Fehlauer, F
    Mahlmann, B
    Marx, M
    Hinke, A
    Sommer, K
    Richter, E
    Feyerabend, T
    STRAHLENTHERAPIE UND ONKOLOGIE, 2003, 179 (06) : 385 - 389
  • [22] Randomized phase II study of concomitant chemoradiation using weekly carboplatin/paclitaxel/concomitant boost radiation with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced head and neck cancer
    Haddad, R.
    Braschayko, P.
    Sonis, S.
    Posner, M.
    Wirth, L.
    Tishler, R.
    ORAL ONCOLOGY, 2009, : 65 - 65
  • [23] Subcutaneous Compared With Intravenous Administration of Amifostine in Patients With Head and Neck Cancer Receiving Radiotherapy: Final Results of the GORTEC 2000-02 Phase III Randomized Trial
    Bardet, Etienne
    Martin, Laurent
    Calais, Gilles
    Alfonsi, Marc
    Feham, Nasr Eddine
    Tuchais, Claude
    Boisselier, Pierre
    Dessard-Diana, Bernadette
    Seng, Sok-Hun
    Garaud, Pascal
    Auperin, Anne
    Bourhis, Jean
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 127 - 133
  • [24] Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
    Argiris, Athanassios
    Karamouzis, Michalis V.
    Gooding, William E.
    Branstetter, Barton F.
    Zhong, Shilong
    Raez, Luis E.
    Savvides, Panayiotis
    Romkes, Marjorie
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1140 - 1145
  • [25] PHASE-II TRIAL OF MITOGUAZONE IN PATIENTS WITH RECURRENT HEAD AND NECK-CANCER
    CONINX, P
    NASCA, S
    JEZEKOVA, D
    ROELANDT, H
    MOREL, M
    LEGROS, M
    CATTAN, A
    BULLETIN DU CANCER, 1985, 72 (02) : 153 - 154
  • [26] PHASE-II TRIAL OF MITOGUAZONE IN PATIENTS WITH ADVANCED HEAD AND NECK-CANCER
    THONGPRASERT, S
    BOSL, GJ
    GELLER, NL
    WITTES, RE
    CANCER TREATMENT REPORTS, 1984, 68 (10): : 1301 - 1302
  • [27] Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer
    Lee, Maverick G. L.
    Freeman, Amanda R.
    Roos, Daniel E.
    Milner, Alvin D.
    Borg, Martin F.
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2019, 63 (01) : 142 - 150
  • [28] Amifostine in the Treatment of Head and Neck Cancer: Intravenous Administration, Subcutaneous Administration, or None of the Above
    Eisbruch, Avraham
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : 119 - 121
  • [29] Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck canceraEuro
    Argiris, A.
    Bauman, J. E.
    Ohr, J.
    Gooding, W. E.
    Heron, D. E.
    Duvvuri, U.
    Kubicek, G. J.
    Posluszny, D. M.
    Vassilakopoulou, M.
    Kim, S.
    Grandis, J. R.
    Johnson, J. T.
    Gibson, M. K.
    Clump, D. A.
    Flaherty, J. T.
    Chiosea, S. I.
    Branstetter, B.
    Ferris, R. L.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1594 - 1600
  • [30] Report from ASCO 2004 - Amifostine reduces radiation therapy-induced dry mouth in head and neck cancer patients
    不详
    ONCOLOGY-NEW YORK, 2004, 18 (10): : 1314 - +
12345